The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 7, 2014, Pages 731-745

  Ginnebaugh, Kevin R ^a   Ahmad, Aamir ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Epithelial to mesenchymal transition; Metastasis

Indexed keywords

FIBULIN; MICRORNA; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST; WNT PROTEIN;

ANGIOGENESIS; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HEDGEHOG; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84902530878     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.909807     Document Type: Review

References (167)

1. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6
2. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005;132:3151-61
3. Katoh M. Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol 2005;27:1677-83
4. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011;27:347-76
5. Thiery JP, Lim CT. Tumor dissemination: an EMT affair. Cancer Cell 2013;23:272-3
6. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014;34:280-300
7. Kong D, Li Y, Wang Z, et al. Cancer stem cells and epithelial-to- mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel) 2011;3:716-29
8. Dandawate D, Padhye S, Ahmad A, et al. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res 2013;3:165-82
9. Bao B, Ahmad A, Azmi AS, et al. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol 2013; Chapter 14
10. Singh S. Breast cancer stem cells and miRNAs. In: Ahmad A, editor. Breast cancer metastasis and drug resistance. Springer, New York; 2012. p. 367-84
11. Liu H, Zhang HW, Sun XF, et al. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties. Chin Med J (Engl) 2013;126:3030-4
12. Korkaya H, Malik F. Breast cancer stem cells: responsible for therapeutic resistance and relapse? In: Ahmad A, editor. Breast cancer metastasis and drug resistance. Springer, New York; 2012. p. 385-98
13. Ahmad A, Li Y, Bao B, Sarkar FH. Resistance and DNA repair mechanisms of cancer stem cells: potential molecular targets for therapy. In: Mathews LA, Cabarcas SM, Hurt EM, editors. DNA repair of cancer stem cells. Springer, New York; 2012. p. 33-52
14. Hsieh CH, Chao KS, Liao HF, et al. Norcantharidin, derivative of cantharidin, for cancer stem cells. Evid Based Complement Alternat Med 2013;2013:838651
15. Owens TW, Naylor MJ. Breast cancer stem cells. Front Physiol 2013;4:225
16. Zhao Y, Bao Q, Schwarz B, et al. Stem cell like side populations in esophageal cancer: a source of chemotherapy resistance and metastases. Stem Cells Dev 2014;23:180-92
17. Mallini P, Lennard T, Kirby J, et al. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2014;40:341-8
18. Castellanos JA, Merchant NB, Nagathihalli NS. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther 2013;6:1261-7
19. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012;22:396-403
20. Sanders MA, Majumdar AP. Colon cancer stem cells: implications in carcinogenesis. Front Biosci (Landmark Ed) 2011;16:1651-62
21. Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 2012;322:1-7
22. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012;2012:708036
23. Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol 2013;19:2603-11
24. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15
25. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009;14:29-43
26. Santisteban M, Reiman JM, Asiedu MK, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009;69:2887-95
27. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009;8:843-52
28. Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009;26:433-46
29. Gu G, Yuan J, Wills M, et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807-15
30. Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888
31. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59
32. Gomez-Casal R, Bhattacharya C, Ganesh N, et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer 2013;12:94
33. Chang L, Graham PH, Hao J, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013;4:e875
34. Mirantes C, Espinosa I, Ferrer I, et al. Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol 2013;44:1973-81
35. Luo X, Dong Z, Chen Y, et al. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif 2013;46:436-46
36. Bessède E, Staedel C, Acuna Amador LA, et al. Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene 2013. [Epub ahead of print]
37. Fan YL, Zheng M, Tang YL, et al. A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett 2013;6:1174-80
38. Charpentier M, Martin S. Interplay of stem cell characteristics, EMT, and microtentacles in circulating breast tumor cells. Cancers (Basel) 2013;5:1545-65
39. Supernat A, Lapinska-Szumczyk S, Majewska H, et al. Epithelial- mesenchymal transition and cancer stem cells in endometrial cancer. Anticancer Res 2013;33:5461-9
40. Masui T, Ota I, Yook JI, et al. Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. Int J Oncol 2014;44:693-9
41. Liu J, Ruan B, You N, et al. Downregulation of miR-200a Induces EMT Phenotypes and CSC-like Signatures through Targeting the beta-catenin Pathway in Hepatic Oval Cells. PLoS One 2013;8:e79409
42. Padua Alves C, Fonseca AS, Muys BR, et al. The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cells lines. Stem Cells 2013;31:2827-32
43. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001;23:912-23
44. De Caene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-108
45. Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res 2013;5:187-95
46. Scanlon CS, Van Tubergen EA, Inglehart RC, et al. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res 2013;92:114-21
47. Choi Y, Lee HJ, Jang MH, et al. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. Hum Pathol 2013;44:2581-9
48. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-18
49. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90
50. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010;101:293-9
51. Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 2012;79:195-208
52. Parvani JG, Schiemann WP. Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res 2013;15:R72
53. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013;27:2192-206
54. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011;307:26-36
55. Gungor C, Zander H, Effenberger KE, et al. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 2011;71:5009-19
56. Xie M, Zhang L, He CS, et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 2012;113:1501-13
57. Matsuno Y, Coelho AL, Jarai G, et al. Notch signaling mediates TGF-beta1-induced epithelialmesenchymal transition through the induction of Snai1. Int J Biochem Cell Biol 2012;44:776-89
58. Du R, Sun W, Xia L, et al. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One 2012;7:e30771
59. Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol 2013;2013:290568
60. Kang J, Kim E, Kim W, et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem 2013;288:27343-57
61. Espinoza I, Miele L. Deadly crosstalk: notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett 2013;341:41-5
62. Wang T, Xuan X, Pian L, et al. Notch-1-mediated esophageal carcinoma EC-9706 cell invasion and metastasis by inducing epithelial-mesenchymal transition through Snail. Tumour Biol 2013. [Epub ahead of print]
63. Espinoza I, Pochampally R, Xing F, et al. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther 2013;6:1249-59
64. Li Y, Ma J, Qian X, et al. Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets 2013;13:957-62
65. Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/beta-catenin pathway in gastric cancer. Dig Dis Sci 2013;58:724-33
66. Zhang Q, Bai X, Chen W, et al. Wnt/ beta-catenin signaling enhances hypoxiainduced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013;34:962-73
67. Cong N, Du P, Zhang A, et al. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/beta-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma. Oncol Rep 2013;29:1579-87
68. Li X, Xu Y, Chen Y, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/betacatenin signal network. Cancer Lett 2013;336:379-89
69. Huang J, Xiao D, Li G, et al. EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells. Oncogene 2013. [Epub ahead of print]
70. Oh SJ, Shin JH, Kim TH, et al. beta-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J Pathol 2013;231:210-22
71. Kim MK, Maeng YI, Sung WJ, et al. The differential expression of TGF-beta1, ILK and wnt signaling inducing epithelial to mesenchymal transition in human renal fibrogenesis: an immunohistochemical study. Int J Clin Exp Pathol 2013;6:1747-58
72. Yang M, Li SN, Anjum KM, et al. A double-negative feedback loop between Wnt-beta-catenin signaling and HNF4alpha regulates epithelialmesenchymal transition in hepatocellular carcinoma. J Cell Sci 2013;126:5692-703
73. Chaudhary SC, Singh T, Talwelkar SS, et al. Erb-041, an estrogen receptor beta agonist inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating WNT signaling pathway. Cancer Prev Res (Phila) 2014;7:186-98
74. Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and RAS/ MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012;72:1878-89
75. Xue G, Restuccia DF, Lan Q, et al. Akt/ PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov 2012;2:248-59
76. Han M, Liu M, Wang Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012;7:e39520
77. Ha GH, Park JS, Breuer EK. TACC3 promotes epithelialmesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett 2013;332:63-73
78. Tsukamoto T, Hama S, Kogure K, et al. Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation. Exp Cell Res 2013;319:1913-21
79. Ahmad A, Biersack B, Li Y, et al. Targeted regulation of PI3K/Akt/mTOR/ NF-kappaB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem 2013;13:1002-13
80. Ahmad A, Biersack B, Li Y, et al. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Anticancer Agents Med Chem 2013;13:1014-24
81. Tan J, You Y, Xu T, et al. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicol Lett 2014;224:7-15
82. Antoon JW, Lai R, Struckhoff AP, et al. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci Rep 2012;2:539
83. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009;69:2400-7
84. Sarkar FH, Li Y, Wang Z, et al. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 2009;64:489-500
85. Sethi S, Sarkar FH, Ahmed Q, et al. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol 2011;4:222-6
86. Bao B, Azmi AS, Ali S, et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim.Biophys. Acta 2012;1826:272-96
87. Hoshino H, Miyoshi N, Nagai K, et al. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem Biophys.Res Commun 2009;390:1061-5
88. Ahmed N, Abubaker K, Findlay J, et al. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010;10:268-78
89. Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011;17:2350-60
90. Chen X, Lingala S, Khoobyari S, et al. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 2011;55:838-45
91. Latifi A, Abubaker K, Castrechini N, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 2011;112:2850-64
92. Marchini S, Fruscio R, Clivio L, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2013;49:520-30
93. Izumiya M, Kabashima A, Higuchi H, et al. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res 2012;32:3847-53
94. Yamada D, Kobayashi S, Wada H, et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 2013;49:1725-40
95. Lim S, Becker A, Zimmer A, et al. SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One 2013;8:e66558
96. Siebzehnrubl FA, Silver DJ, Tugertimur B, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 2013;5:1196-212
97. Ni J, Cozzi P, Hao J, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/ Akt/mTOR signaling pathway. Int J Biochem Cell Biol 2013;45:2736-48
98. Hara J, Miyata H, Yamasaki M, et al. Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer. Oncol Rep 2014;31:589-96
99. Goldberg SB, Oxnard GR, Digumarthy S, et al. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resisitance to egfr tyrosine kinase inhibitors. Oncologist 2013;18:1214-20
100. Maseki S, Ijichi K, Tanaka H, et al. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br J Cancer 2012;106:1196-204
101. Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-53
102. Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007;31:277-83
103. Du F, Wu X, Liu Y, et al. Acquisition of paclitaxel resistance via PI3Kdependent epithelialmesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep 2013;30:1113-18
104. Zhang P, Liu H, Xia F, et al. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med 2014;33:151-9
105. Wang H, Zhang G, Zhang H, et al. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/betacatenin/ Snail signaling pathway. Eur J Pharmacol 2014;723:156-66
106. Zhang W, Feng M, Zheng G, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012;417:679-85
107. Maitah MY, Ali S, Ahmad A, et al. Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One 2011;6:e16068
108. Ahmad A, Maitah MY, Ginnebaugh KR, et al. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMTregulating miRNAs. J Hematol Oncol 2013;6:77
109. Wu Q, Wang R, Yang Q, et al. Chemoresistance to gemcitabine in hepatoma cells induces epithelialmesenchymal transition and involves activation of PDGF-D pathway. Oncotarget 2013;4:1999-2009
110. Gupta N, Xu Z, El-Sehemy A, et al. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatininduced apoptosis in ovarian cancer cells. Gynecol Oncol 2013;130:200-6
111. Qu C, Zhang W, Zheng G, et al. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem 2014;386:63-71
112. Yang J, Yu H, Shen M, et al. N1- guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation. Cancer Sci 2014;105:219-27
113. Canadas I, Rojo F, Taus A, et al. Targeting epithelial to mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res 2014;20:938-50
114. Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012;12:91
115. Zhuo WL, Wang Y, Zhuo XL, et al. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun 2008;369:1098-102
116. Zhuo W, Wang Y, Zhuo X, et al. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer 2008;62:8-14
117. Ren J, Chen Y, Song H, et al. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem 2013;114:1395-403
118. Xing F, Okuda H, Watabe M, et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 2011;30:4075-86
119. Espinoza I, Pochampally R, Xing F, et al. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther 2013;6:1249-59
120. Sumual S, Saad S, Tang O, et al. Differential regulation of Snail by hypoxia and hyperglycemia in human proximal tubule cells. Int J Biochem Cell Biol 2010;42:1689-97
121. Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxiainduced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008;105:6392-7
122. Wang ZS, Shen Y, Li X, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumour Biol 2014;35:1357-63
123. Palagani V, El KM, Kossatz U, et al. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/ EpCAM+ cells are inhibited by gamma-secretase inhibitor IX. PLoS One 2012;7:e46514
124. Groth C, Fortini ME. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012;23:465-72
125. Sethi S, Macoska J, Chen W, et al. Molecular signature of epithelialmesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010;3:90-9
126. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7
127. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26
128. Kim J, Hwan KS. CK2 inhibitor CX-4945 blocks TGF-beta1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells. PLoS One 2013;8:e74342
129. Martins LR, Lucio P, Melao A, et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 2014;28:179-82
130. Ahmad A, Sarkar SH, Bitar B, et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther 2012;11:2193-201
131. Ahmad A, Padhye S, Sarkar FH. Role of novel nutraceuticals garcinol, plumbagin and mangiferin in the prevention and therapy of human malignancies: mechanisms of anticancer activity. In: Sarkar FH, editor. Nutraceuticals and cancer. Springer; New York: 2012. p. 179-99
132. Suman S, Kurisetty V, Das TP, et al. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells. Mol Carcinog 2014;53(Suppl 1):E151-60
133. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 kinase/AKT pathways. Oncogene 2005;24:7443-54
134. Fenouille N, Tichet M, Dufies M, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 2012;7:e40378
135. Lau MT, Leung PC. The PI3K/Akt/ mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett 2012;326:191-8
136. Wang H, Fang R, Wang XF, et al. Stabilization of Snail through AKT/ GSK-3beta signaling pathway is required for TNF-alpha-induced epithelialmesenchymal transition in prostate cancer PC3 cells. Eur J Pharmacol 2013;714:48-55
137. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8:2369-77
138. Li Y, Wang Z, Kong D, et al. Regulation of Akt/FOXO3a/GSK-3beta/ AR signaling network by isoflavone in prostate cancer cells. J Biol Chem 2008;283:27707-16
139. Gajula RP, Chettiar ST, Williams RD, et al. The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res 2013;11:1387-400
140. Mao Y, Xu J, Song G, et al. Twist2 promotes ovarian cancer cell survival through activation of Akt. Oncol Lett 2013;6:169-74
141. Fan CC, Wang TY, Cheng YA, et al. Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma. J Cancer Res Clin Oncol 2013;139:1735-44
142. Wang X, Liu Q, Hou B, et al. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS One 2013;8:e73942
143. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemnessinhibiting microRNAs. Nat Cell Biol 2009;11:1487-95
144. Mao J, Zhang Q, Ye X, et al. Efficient induction of pluripotent stem cells from granulosa cells by oct4 and sox2. Stem Cells Dev 2014;23(7):779-89
145. Herreros-Villanueva M, Zhang JS, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem celllike features to pancreatic cancer cells. Oncogenesis 2013;2:e61
146. Kim IG, Kim SY, Choi SI, et al. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene 2013. [Epub ahead of print]
147. Wang ML, Chiou SH, Wu CW. Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther 2013;6:1207-20
148. Luo W, Li S, Peng B, et al. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One 2013;8:e56324
149. Mimeault M, Batra SK. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med 2013. [Epub ahead of print]
150. Tang J, Ahmad A, Sarkar FH. The role of microRNAS in breast cancer migration, invasion and metastasis. Int J Mol Sci 2012;13:13414-37
151. Ali AS, Ahmad A, Ali S, et al. The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis. J Cell Physiol 2013;228:36-42
152. Li Y, Ahmad A, Kong D, et al. Targeting MicroRNAs for personalized cancer therapy. Med Princ Pract 2013;22:415-17
153. Ahmad A, Ali AS, Ali S, et al. MicroRNAs: targets of interest in breast cancer research. In: Mulligan JA, editor. MicroRNA: expression, detection and therapeutic strategies. Nova Publishers, New York; 2011. p. 59-78
154. Ahmed A, Ali AS, Ali S, et al. MicroRNAs in breast cancer research: progress and promise. In: Ahmad A, editor. Breast cancer metastasis and drug resistance. Springer, New York; 2012. p. 399-413
155. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010;5:e12445
156. Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013;62:1315-26
157. Song SJ, Poliseno L, Song MS, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013;154:311-24
158. Roy SS, Gonugunta VK, Bandyopadhyay A, et al. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene 2013. [Epub ahead of print]
159. Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 2012;66:397-402
160. Wang L, Yuan C, Lv K, et al. Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling. PLoS One 2013;8:e67373
161. Tang Z, Ow GS, Thiery JP, et al. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer 2014;134:306-18
162. Bhutia YD, Hung SW, Krentz M, et al. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. PLoS One 2013;8:e53436
163. Sugimura K, Miyata H, Tanaka K, et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/ STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012;18:5144-53
164. Li Y, VandenBoom TG, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009;69:6704-12
165. Moes M, Le BA, Crespo I, et al. A novel network integrating a miRNA-203/ SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One 2012;7:e35440
166. Ding X, Park SI, McCauley LK, et al. Signaling between transforming growth factor beta (TGF-beta) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem 2013;288:10241-53
167. Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelialmesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011;71:3400-9